Q-omics provides the consensus-scored ZNF853 profile across patient tissues and cancer cell-line models. ZNF853 expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, ZNF853 is differentially expressed in 17, with the highest sampling consensus in KIRC. Additionally, ZNF853 RNA expression shows 19,627 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight BRCA, KIRC, and GBM as cancer lineages where ZNF853 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF853 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF853 survival associations across molecular data types. ZNF853 RNA expression shows survival associations in the most cancer types (29), followed by mutation status (3) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF853 RNA expression–survival associations across cancer types. High ZNF853 expression shows unfavorable associations in ACC, but favorable associations in BRCA, UVM, KICH, SCLC and PAAD. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for ZNF853 RNA expression.
This table summarizes ZNF853 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for ZNF853. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF853 shows lower tumor expression in KIRC, KICH, THCA, BRCA, UCEC and HNSC. The KIRC box plot shows higher ZNF853 RNA expression in normal versus tumor tissue (log2 FC = −1.316, t-test p < 0.001).
This table shows molecular features associated with ZNF853 in patient tissues and cancer cell lines. In patient samples, ZNF853 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF853 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BONE.
